Drug Overview: Latuda

  • ID: 4533521
  • Report
  • 33 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.

In 2011, Sumitomo Dainippon and Takeda entered into an agreement for the joint development and commercialization of Latuda in the EU (except for in the UK, where Sumitomo Dainippon retained exclusive rights), for the treatment of schizophrenia and bipolar disorder. Takeda terminated this alliance in May 2015, with all rights transferring back to Sumitomo Dainippon’s subsidiary Sunovion Pharmaceuticals. In November 2017, Sumitomo Dainippon announced a partnership with Angelini for the marketing and commercialization of Latuda in 29 European countries. While Sumitomo Dainippon will continue to supply Latuda in some EU countries including the UK, Angelini is now responsible for Latuda’s expansion to other countries. Latuda’s launch in Italy at the end of 2017 marked the first fruits of this strategic partnership.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW
Drug Overview
Product Profiles
Latuda: Bipolar disorder
Latuda: Schizophrenia

List of Figures
Figure 1: Latuda for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Latuda in bipolar disorder
Figure 3: Drug assessment summary for Latuda in bipolar disorder
Figure 4: Latuda for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Latuda for schizophrenia
Figure 6: Drug assessment summary of Latuda for schizophrenia
Figure 7: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country, 2017-26

List of Tables
Table 1: Latuda bipolar disorder indication approvals
Table 2: Latuda drug profile
Table 3: Overview of pivotal Phase III PREVAIL trials of Latuda in adults with bipolar depression
Table 4: Adverse reactions in =5% of Latuda-treated adult patients in bipolar depression studies
Table 5: Overview of the Phase III ILLUMINATE trial of Latuda in adolescents and children with bipolar depression
Table 6: Adverse reactions in =5% of Latuda-treated pediatric patients in bipolar depression studies
Table 7: Overview of key Japanese clinical trial data for Latuda in bipolar disorder
Table 8: Overview of clinical trial data for Latuda in maintenance treatment of bipolar I disorder
Table 9: Latuda drug profile
Table 10: Latuda pivotal trial data in schizophrenia
Table 11: Latuda other late-phase trial data in schizophrenia
Table 12: Latuda sales for schizophrenia across the US, Japan, Germany, Italy, Spain, and the UK, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll